

Filed On Behalf Of:

Novartis AG and LTS Lohmann Therapie-Systeme AG

By:

Raymond R. Mandra
ExelonPatchIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS INC.,
Petitioner

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners

Inter Partes Review No. 2014-00549

U.S. Patent 6,316,023

PRELIMINARY RESPONSE BY
PATENT OWNERS PURSUANT TO 37 C.F.R. § 42.107

TABLE OF CONTENTS

I.	35 U.S.C. § 315(a) Bars Noven’s Petition.....	1
II.	The Board Should Deny Institution Of Noven’s Petition In View Of Pending Delaware District Court Litigation.....	6
III.	The Board Should Reject Noven’s Proposed Construction Of The Claim Term “Comprising”	8
IV.	The Board Should Exclude Rosin, Elmalem And Ebert From Ground 1 Because They Are Redundant	12
V.	The Board Should Exclude Rosin And Ebert From Ground 2 Because They Are Redundant	15
VI.	The Board Should Exclude Ebert From Ground 3 Because It Is Redundant	16
VII.	The Board Should Exclude Ebert From Ground 4 Because It Is Redundant	17
VIII.	The Board Should Deny Institution Of Ground 5 Because It Is Redundant Of Grounds 1-3.....	18
IX.	The Board Should Deny Institution Of Ground 6 Because It Is Redundant Of Ground 4	20
X.	Conclusion	21

TABLE OF AUTHORITIES

Cases

<i>Accord Healthcare, Inc. USA v. Eli Lilly & Co.</i> , IPR2013-00356 (P.T.A.B. Oct. 1, 2013) (Paper 13)	5
<i>Anova Food, LLC. v. Leo Sandau</i> , IPR2013-00114 (P.T.A.B. June 25, 2013) (Paper 11)	6
<i>Eli Lilly and Co. v. Medtronic, Inc.</i> , 496 U.S. 661 (1990).....	2
<i>Fresenius USA, Inc. v. Baxter Int’l, Inc.</i> , 721 F.3d 1330 (Fed. Cir. 2013)	8
<i>Illumina, Inc. v. Trustees of Columbia Univ. in the City of New York</i> , IPR2012-00006 (P.T.A.B. May 10, 2013) (Paper 43)	12, 14
<i>In re Ciprofloxacin Hydrochloride Antitrust Litig.</i> , 544 F.3d 1323 (Fed. Cir. 2008)	3
<i>In re Rosuvastatin Calcium Patent Litig.</i> , 703 F.3d 511 (Fed. Cir. 2012)	3
<i>In re Rosuvastatin Calcium Patent Litig.</i> , MDL No. 08-1949, 2008 WL 5046424 (D. Del. Nov. 24, 2008)	8
<i>Intelligent Bio-Sys, Inc. v. Illuminia Cambridge Ltd.</i> , IPR2013-00324 (P.T.A.B. Nov. 21, 2013) (Paper 19).....	7
<i>Liberty Mutual Ins. Co. v. Progressive Casualty Ins. Co.</i> , CBM2012-00003 (P.T.A.B. Oct. 25, 2012) (Paper 7)	12, 13, 18, 20
<i>Motorola Mobility LLC v. Arnouse</i> , IPR2013-00010 (P.T.A.B. Jan. 30, 2013) (Paper 20)	5
<i>Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.</i> , 267 F. Supp. 2d 533 (N.D. W. Va. 2003).....	10
<i>Power Mosfet Techs., L.L.C. v. Siemens AG</i> , 378 F.3d 1396 (Fed. Cir. 2004)	11

Spectrum Int'l, Inc. v. Sterlite Corp.,
164 F.3d 1372 (Fed. Cir. 1998)11

Teva Neuroscience, Inc. v. Watson Labs., Inc.,
No. 2:10-cv-05078, 2013 WL 1595585 (D.N.J. April 12, 2013).....10

Texas Instruments Inc. v. U.S. Int'l Trade Comm'n,
988 F.2d 1165 (Fed. Cir. 1993)11

Statutes

21 U.S.C. § 355(j) 1

21 U.S.C. § 355(j)(2)(A)(vii)(IV)2, 3

21 U.S.C. § 355(j)(2)(B)(iv)(II)2

21 U.S.C. § 355(j)(5)(C)(i)3

35 U.S.C. § 271(e)(2).....2

35 U.S.C. § 3147

35 U.S.C. § 314(d)7

35 U.S.C. § 3154, 6

35 U.S.C. § 315(a) 1, 4, 21

35 U.S.C. § 315(b)4, 5

Regulations

37 C.F.R. § 42.107(c).....6

37 C.F.R. § 42.108(a)..... 12, 16, 17, 18

Novartis AG and LTS Lohmann Therapie-Systeme AG (“Patent Owners”) respectfully submit this Preliminary Response to the Petition of Noven Pharmaceuticals Inc. (“Noven”) seeking *inter partes* review (“IPR”) of U.S. Patent No. 6,316,023 (“’023 patent”).

I. 35 U.S.C. § 315(a) Bars Noven’s Petition

35 U.S.C. § 315(a) provides that “[a]n inter partes review may not be instituted if, before the date on which the petition for such a review is filed, the petitioner . . . filed a civil action challenging the validity of a claim of the patent.” Noven effectively filed a civil action challenging the validity of a claim of the ‘023 patent before the date of its petition. Its petition thus is barred by 35 U.S.C. § 315(a).

Noven is seeking approval from the United States Food and Drug Administration (“FDA”) under 21 U.S.C. § 355(j) of the Hatch-Waxman Act to market a generic copy of Novartis’s Exelon® Patch rivastigmine transdermal device, which is indicated for the treatment of mild to moderate dementia associated with Alzheimer’s disease and Parkinson’s disease. On April 2, 2014, Noven filed the instant petition challenging the validity of claims 1, 2, 4, 5, 7 and 8 of the ‘023 patent. More than one year before, and prior to February 18, 2013, Noven filed with the FDA a certification

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.